Hepatitis C virus: A time for decisions. Who should be treated and when?
Author:
Publisher
Baishideng Publishing Group Inc.
Reference56 articles.
1. Management of HCV patients with cirrhosis with direct acting antivirals
2. How to optimize HCV therapy in genotype 1 patients with cirrhosis
3. Patients with HCV and F1 and F2 fibrosis stage: treat now or wait?
4. The new paradigm of hepatitis C therapy: integration of oral therapies into best practices
5. Barriers to Hepatitis C Antiviral Therapy in HIV/HCV Co-Infected Patients in the United States: A Review
Cited by 20 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Relation between chronic hepatitis C infection and different radiological patterns of interstitial lung disease;The Egyptian Journal of Chest Diseases and Tuberculosis;2023
2. Conspicuous Response to Direct-Acting Antivirals in Chronic Hepatitis C-related Immune Thrombocytopenia: A Case Report;Cureus;2022-04-16
3. The impact of single‑nucleotide polymorphisms on liver stiffness and controlled attenuation parameter in patients treated with direct‑acting antiviral drugs for hepatitis C infection;Biomedical Reports;2021-12-07
4. NS34A resistance-associated substitutions in chronic hepatitis C in Upper Egypt and regression of liver fibrosis after direct-acting antiviral therapy;Egyptian Liver Journal;2021-02-01
5. Timing of DAA Initiation After Curative Treatment and Its Relationship with the Recurrence of HCV-Related HCC;Journal of Hepatocellular Carcinoma;2020-12
Timing of DAA Initiation After Curative Treatment and Its Relationship with the Recurrence of HCV-Related HCC
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3